FDA Drops Black Box Warning on Menopause Hormone Therapy, Backing 80% to 90% Symptom Relief
Updated
Updated · Norton Healthcare · Aug 6
FDA Drops Black Box Warning on Menopause Hormone Therapy, Backing 80% to 90% Symptom Relief
3 articles · Updated · Norton Healthcare · Aug 6
Summary
FDA updated menopause hormone therapy safety guidance and removed the long-standing black box warning, a shift that clinicians say broadens treatment options for millions with hot flashes, sleep disruption and mood changes.
Newer evidence drove the change after the early-2000s Women’s Health Initiative chilled prescribing; a large Danish study found women starting estradiol around age 50 had a 50% lower all-cause death risk and no higher breast-cancer risk.
Transdermal estrogen patches and gels are now emphasized because they bypass the liver and cut blood-clot risk versus oral therapy, while micronized progesterone protects the uterus and can also help sleep.
Treatment is now individualized rather than capped at the lowest dose for five years, and symptom relief—not hormone lab targets—guides care; MHT is still inappropriate for women with prior stroke, heart attack, blood clots or breast cancer.